Annual report pursuant to Section 13 and 15(d)

Organization and Description of Business Operations

v3.8.0.1
Organization and Description of Business Operations
12 Months Ended
Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]
 
Note 1 - Organization and Description of Business Operations
 
Checkpoint Therapeutics, Inc. (the “Company” or “Checkpoint”) was incorporated in Delaware on November 10, 2014. Checkpoint is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company may acquire rights to these technologies by licensing the rights or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. The Company may also enter into collaboration agreements with third and related parties including sponsored research agreements to develop these technologies for liquid tumors while retaining the rights in solid tumors.
 
The Company is a majority-controlled subsidiary of Fortress Biotech, Inc. (“Fortress”).
 
The Company’s common stock is listed on the NASDAQ Capital Market and trades under the symbol “CKPT.”
    
Liquidity and Capital Resources
 
The Company has incurred substantial operating losses since its inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of December 31, 2017, the Company had an accumulated deficit of $59.0 million.
 
In March 2018, the Company announced the pricing of an underwritten public offering, whereby it sold 4,600,000 shares of its common stock (plus a 45-day option to purchase up to an additional 690,000 shares of common stock, which has been exercised) at a price of $4.35 per share for gross proceeds of approximately $23.0 million. Total net proceeds from this offering, including the overallotment, are expected to be approximately $20.9 million, net of underwriting discounts and estimated offering expenses of approximately $2.1 million. The shares were sold under a Registration Statement (No. 333-221493) on Form S-3, filed by the Company with the Securities and Exchange Commission. The offering closed on March 12, 2018.
 
The Company expects to continue to use the proceeds from previous financing transactions primarily for general corporate purposes, which may include financing the Company’s growth, developing new or existing product candidates, and funding capital expenditures, acquisitions and investments. The Company currently anticipates that its cash and cash equivalents balances at December 31, 2017 combined with the additional capital raised in the first quarter of 2018, are sufficient to fund its anticipated operating cash requirements for approximately the next 18 to 21 months.